Related Experiment Videos
CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues
Achim A Jungbluth1, Yao-Tseng Chen, Klaus J Busam
1Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. jungblua@mskcc.org
International Journal of Cancer
|July 13, 2002
Summary
A new monoclonal antibody (MAb), CT7-33, was developed to detect CT7 (MAGE-C1) protein. This antibody confirmed CT7 expression in normal testicular germ cells and various tumors, highlighting frequent antigen heterogeneity.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer-testis (CT) antigens, such as CT7 (MAGE-C1), are a class of tumor antigens with restricted expression in normal tissues but widespread presence in various cancers.
- Understanding the protein expression patterns of CT antigens is crucial for developing targeted cancer therapies and diagnostic tools.
Purpose of the Study:
- To generate and characterize a novel monoclonal antibody (MAb), CT7-33, for the detection of CT7 protein.
- To analyze the protein expression profile of CT7 in normal adult tissues and a range of neoplastic lesions using the developed MAb.
- To correlate protein expression with existing mRNA data and assess the diagnostic potential of CT7 as a tumor marker.
Main Methods:
- Generation of a specific monoclonal antibody (CT7-33) against the CT7 antigen.
- Immunohistochemistry (IHC) on frozen and formalin-fixed paraffin-embedded tissues for protein expression analysis.
- Reverse transcriptase polymerase chain reaction (RT-PCR) for mRNA expression analysis.
- Co-typing of IHC and RT-PCR to confirm antibody specificity and expression patterns.
Main Results:
- CT7-33 demonstrated effective immunoreactivity in both frozen and fixed tissues, with specificity confirmed by IHC/RT-PCR co-typing.
- Normal adult tissue expression of CT7 was exclusively observed in testicular germ cells.
- CT7 protein expression was detected in tumor cells across various neoplastic lesions, largely correlating with mRNA expression data.
- High CT7 protein expression incidence was noted in mammary gland and ovarian carcinomas, non-small cell lung carcinoma, and metastatic melanomas.
- Colorectal and renal cell carcinomas, along with sarcomas, showed minimal to no CT7-33 staining.
- Tumor expression patterns were predominantly heterogeneous, with infrequent observation of staining in over 50% of tumor cells.
Conclusions:
- The study successfully generated CT7-33, a valuable serologic reagent for assessing CT7 protein expression.
- The findings confirm the restricted expression of CT7 in normal tissues and its presence in specific tumor types.
- The prevalent heterogeneity of CT7 protein expression in tumors, consistent with other CT antigens, underscores the complexity of targeting these antigens for therapy.